US Patent and Trademark Office Allows Reven’s Patent Application to Issue as a New Patent

Reven Holdings, Inc. (“Reven”) is a privately held clinical stage biotechnology and pharmaceutical company dedicated to the discovery and development of novel treatment platforms for cancer, cardiovascular and metabolic disorders, viral illnesses—including COVID-19—and inflammatory disorders. The lead anti-inflammatory/anti-oxidant investigational drug product Rejuveinix (RJX) is being